IOSP

Innospec Inc. Materials Chemicals & Allied Products Russell 3000

$99.89Close $3.0BMarket cap $65.12 – $101.4152-week range Nov 3, 2026Next report · after the close

Stage 2 Leader 54th of 68

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 82 · stronger than 82% of stocks over 12 months
RS line at a 1-year high outperforming the S&P 500 more than at any point this year
Near its high 1% below its 52-week high
Tight base near its pivot pullbacks 7% → 4%; 0.7% above its $99.22 pivot
Earnings growing EPS +33% year on year, faster than the quarter before (+39 pts)

Cautions

Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026

Off 12-month high 1%

1wk 1.3% price change

1mo 4.8% price change

12-month return 40% market up 11% · its own up 28%

F-score 7 / 9 Strong

Altman Z 6.01 Low risk

P/E 25.3× price / earnings

PEG 0.11 P/E / EPS growth

P/B 2.2× price / book

Earnings yield 4.9% EBIT / enterprise value

Cheaper than 65% of the market · cheap

Revenue growth 4% year on year

EPS growth 33% latest quarter · +39 pts

Sales growth 12% latest quarter · +9 pts

ROE 9% return on equity

Free cash margin 8% $138.3M FCF

D/E — long-term debt / equity

Net debt / EBITDA -1.7× net cash

Interest cover —EBIT / interest

Piotroski tests

gross margin narrowed
assets working less efficiently
profitable on its assets
generating cash from operations
profitability improving
profits backed by cash
reduced long-term debt
short-term liquidity improved
no new shares issued

Trade setup

ATR% 1.9% $1.93 a day · 2×ATR $96.04

RS 82 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 1.0× vs 50-day average

Up/down volume 1.15 50 sessions

Implied move — no option chain · report Nov 3, 2026

Contractions 2 7% → 4%

Pivot $99.22 0.7% above

Volume dry-up 1.2× 10 vs 50 sessions

Trend template · 8 of 8

Screen verdict

1 of 3 screens

Stage 2 Leader in mixed conditions
- RS 82
- Trend 8/8
- Off 12-month high 1%
- EPS growth +33% (accel +39 pts)
- Sales growth +12% (accel +9 pts)
- Altman Z 6.01 (low risk)

Warning signs

2 flagged

Gross margin narrowing Gross margin fell from 29.4% to 27.7%. The company is keeping less of each dollar of sales than it did a year ago.
Revenue shrinking Revenue fell 3.7% over the year, from $1.8B to $1.8B.

Last reported Aug 5, 2026

Results reaction Aug 5, 2026+6% vs market2 sessions after results

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $1.8B -4% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $116.6M +228% on FY2024

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $138.3M -25% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 28%
Net 7%
Free cash 8%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 29.55m +0.0% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$1.2B	$1.5B	$2.0B	$1.9B	$1.8B	$1.8B
Gross margin	29%	29%	30%	30%	29%	28%
Operating income	$33.7M	$132.1M	$187.3M	$161.6M	$177.9M	$129.5M
Net income	$28.7M	$93.1M	$133.0M	$139.1M	$35.6M	$116.6M
Net margin	2%	6%	7%	7%	2%	7%
Earnings per share	$1.16	$3.75	$5.32	$5.56	$1.42	$4.67
Free cash flow	$145.9M	$93.2M	$81.7M	$207.3M	$184.5M	$138.3M
Free cash margin	12%	6%	4%	11%	10%	8%
Cash	$105.3M	$141.8M	$147.1M	$203.7M	$289.2M	$292.5M
Long-term debt	$0	—	—	—	—	—
Shareholders' equity	$944.4M	$1.0B	$1.0B	$1.1B	$1.2B	$1.3B
Shares outstanding	29.55m	29.55m	29.55m	29.55m	29.55m	29.55m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 5, 2026	Quarterly ↗	Jun 30, 2026	36d
May 8, 2026	Quarterly ↗	Mar 31, 2026	38d
Feb 18, 2026	Annual ↗	Dec 31, 2025	49d
Nov 5, 2025	Quarterly ↗	Sep 30, 2025	36d
Aug 6, 2025	Quarterly ↗	Jun 30, 2025	37d
May 9, 2025	Quarterly ↗	Mar 31, 2025	39d
Feb 19, 2025	Annual ↗	Dec 31, 2024	50d
Nov 6, 2024	Quarterly ↗	Sep 30, 2024	37d
Aug 7, 2024	Quarterly ↗	Jun 30, 2024	38d
May 10, 2024	Quarterly ↗	Mar 31, 2024	40d
Feb 14, 2024	Annual ↗	Dec 31, 2023	45d
Nov 8, 2023	Quarterly ↗	Sep 30, 2023	39d

Current reports

Filed	Disclosed
Aug 5, 2026	Results ↗
Jun 4, 2026	Director or officer change ↗
May 13, 2026	Shareholder vote ↗
May 8, 2026	Results · Regulation FD ↗
Feb 18, 2026	Results ↗
Nov 5, 2025	Results · Regulation FD ↗
Aug 6, 2025	Results ↗
May 14, 2025	Shareholder vote ↗
May 9, 2025	Results · Regulation FD ↗
Mar 11, 2025	Regulation FD ↗
Feb 19, 2025	Results ↗
Nov 6, 2024	Results · Regulation FD ↗